Cancer treatment has evolved beyond traditional chemotherapy and radiation. Immunotherapy drugs like Keytruda (pembrolizumab) are now part of the conversation for many patients, offering a different way to harness the body's own defenses. Read on to learn what Keytruda is, how it works for melanoma and other cancers, and what you should know before discussing it with your doctor.

What Is Keytruda and How Immunotherapy Works

Keytruda is the brand name for a medication called pembrolizumab. It belongs to a class of drugs known as checkpoint inhibitors. According to the American Cancer Society, these treatments block specific proteins that can prevent immune cells from attacking cancer. In doing so, they may help the immune system recognize and destroy cancer cells more effectively. Keytruda is given as an intravenous infusion, typically every three or six weeks depending on the dosing schedule.

Keytruda Melanoma Treatment and Approved Uses

For patients with melanoma, Keytruda has become an important treatment option. The term pembrolizumab melanoma is often used in medical discussions to refer to this specific use. Pembro melanoma therapy has been evaluated in earlier-stage and advanced disease. In Keytruda melanoma clinical practice, the drug can be used after surgery to reduce the risk of recurrence or for metastatic disease. For Keytruda metastatic melanoma, treatment may be given alone or in combination with other approaches depending on previous therapy. The National Cancer Institute lists pembrolizumab among the checkpoint inhibitors used for advanced melanoma.

Important Considerations Before Starting Keytruda

Before beginning treatment, you and your oncology team will assess several factors. Because Keytruda affects the immune system, it can cause immune-related reactions in different parts of the body. These may involve the lungs, liver, skin, or hormone-producing glands. However, not everyone experiences them, and your care team will monitor you closely. It is essential to discuss your full medical history, including any autoimmune conditions, because Keytruda may not be appropriate for everyone. According to the FDA, patients should inform their healthcare provider about all medical conditions. Key points to discuss include:

  • Your specific cancer diagnosis and stage, because Keytruda is only approved for certain types and settings.
  • Results of any biomarker testing, such as PD-L1 expression, which can help predict response.
  • Your overall health, including kidney, liver, and heart function, as these can influence treatment decisions.
  • Any current medications or supplements, including those that affect the immune system.

What to Expect During Treatment

If you and your doctor decide to move forward, you will typically receive the infusion at a clinic or hospital. The process can take 30 to 60 minutes, and you will be observed for a short period afterward. Many people are able to continue daily activities between treatments, though fatigue can occur. Your medical team will schedule regular follow-ups, including blood tests and imaging, to assess how well the treatment is working. According to the American Society of Clinical Oncology, communication with your care team is key to managing any new symptoms promptly.

Keytruda represents a significant step forward in immunotherapy for certain cancers, particularly melanoma. Understanding how it works, who it may help, and what to discuss with your doctor can empower you to make informed choices. If you or a loved one has been diagnosed with melanoma or another cancer for which Keytruda is approved, consider having a detailed conversation with an oncologist. Learning about all available options is the first step toward a personalized treatment plan.